Yttrium 90-labelled edotreotide

Drug Profile

Yttrium 90-labelled edotreotide

Alternative Names: 90Y-SDZ-SMT-487; 90Y-DOTA-D-Phe1-Tyr3-octreotide; 90Y-SMT 487; OctreoTher™; Onalta; SMT-487; Y-90 SMT-487; Y-90-DOTA-tyr3-Octreotide; Yttrium 90 labelled endotreotide; Yttrium 90 labelled SMT 487

Latest Information Update: 11 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Molecular Insight Pharmaceuticals; University of Iowa
  • Class Antineoplastics; Cyclic peptides; Organotechnetium compounds; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuroendocrine tumours

Most Recent Events

  • 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
  • 06 Aug 2010 Yttrium 90-labelled edotreotide is still in phase II trials for Neuroendocrine tumours in USA
  • 04 Sep 2009 Yttrium 90-labelled edotreotide sub-licensed to BioMedica Life Sciences in specific countries in Europe, the Middle East, North Africa, Russia, and Turkey
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top